NUCLEIS

Liege, Belgium Founded: 2017 • Age: 9 yrs Acquired By Curium
PET radio-pharmaceutical drugs are manufactured under contract.
Request Access

About NUCLEIS

NUCLEIS is a company based in Liege (Belgium) founded in 2017 was acquired by Curium in April 2025.. The company has 13 employees as of December 31, 2021. NUCLEIS operates in a competitive market with competitors including Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.

  • Headquarter Liege, Belgium
  • Employees 13 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Nucleis
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    13

    as on Dec 31, 2021

  • Acquired by
    Curium

    (Apr 10, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of NUCLEIS

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in NUCLEIS

NUCLEIS has secured backing from 1 investor. Prominent investors backing the company include Curium Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Curium Pharma is recognized as a leader in radiopharmaceuticals.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by NUCLEIS

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - NUCLEIS

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Nucleis Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of NUCLEIS

NUCLEIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of antibody discovery, cell line development, and bio analytics services
domain founded_year HQ Location
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
domain founded_year HQ Location
Provider of contract research and manufacturing services for both small molecules and biologics
domain founded_year HQ Location
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
domain founded_year HQ Location
Developer of biosimilars, vaccines and natural products
domain founded_year HQ Location
Provides enabling tools and services in the life sciences research and bio-production industries
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Nucleis

Frequently Asked Questions about NUCLEIS

When was NUCLEIS founded?

NUCLEIS was founded in 2017.

Where is NUCLEIS located?

NUCLEIS is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.

Who is the current CEO of NUCLEIS?

Fabrice Giacomelli is the current CEO of NUCLEIS.

How many employees does NUCLEIS have?

As of Dec 31, 2021, the latest employee count at NUCLEIS is 13.

What does NUCLEIS do?

NUCLEIS was established in 2017 in Liege, Belgium, where operations are centered on contract manufacturing within the nuclear medicine sector. PET radio-pharmaceutical drugs are produced for positron emission tomography applications in medical diagnostics. Services encompass formulation, synthesis, and quality control processes tailored to client specifications. The focus remains on regulatory compliance and supply chain efficiency for pharmaceutical partners across Europe.

Who are the top competitors of NUCLEIS?

NUCLEIS's top competitors include Abzena, Syngene and Grand River Aseptic Manufacturing.

Who are NUCLEIS's investors?

NUCLEIS has 1 investor. Key investors include Curium Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available